CoV

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South

Retrieved on: 
Monday, February 8, 2021
Zoonoses, Severe acute respiratory syndrome-related coronavirus, CoV, Severe acute respiratory syndrome, Epidemiology, Medicine, Health

Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit.

Key Points: 
  • Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit.
  • GC MS is an industry leader in the field of medical devices and diagnostic reagents, and a member of the GC Pharmaceutical companies, in South Korea.
  • T-SPOT Discovery SARS-CoV-2 will enable them to add a research test to measure the T cell response to SARS-CoV-2 infection to their offering.
  • Walt Ling, VP commercial APAC for Oxford Immunotec said, We are delighted to work in partnership with GC MS.

Oragenics Announces Closing of $6.5 Million Registered Direct Offering

Retrieved on: 
Tuesday, December 29, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Initial public offering, Prospectus, Registration statement, CoV, Stock market

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the closing of its previously announced registered direct offering of 14,444,444 shares of common stock at a purchase price of $0.45 per share.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the closing of its previously announced registered direct offering of 14,444,444 shares of common stock at a purchase price of $0.45 per share.
  • The gross proceeds from this offering were $6.5 million before deducting the placement agents fees and other offering expenses payable by the Company.
  • The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • Forward-looking statements in this press release include statements about the intended use of net proceeds from the registered direct offering.

Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

Retrieved on: 
Monday, September 28, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical research, Medicine, Health, Respiratory diseases, COVID-19 vaccine, Biomedical Advanced Research and Development Authority, Barda, CoV, Severe acute respiratory syndrome, Vaccines, Terra CoV-2, Oragenics, Inc.

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2.
  • Oragenics has been informed by the Biomedical Advanced Research and Development Authority (BARDA) of BARDAs determination not to enter into negotiation with the Company.
  • Although we are disappointed with BARDAs funding decision, we will continue to pursue other sources of non-dilutive funding of grants and corporate partnerships, and possibly equity capital to advance development of our promising vaccine.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Nutriband Inc. Signs Exclusive Distribution Agreement With Oran Textiles for Cifra Reusable V-Block Coated Facemasks

Retrieved on: 
Tuesday, September 15, 2020
Sarbecovirus, Zoonoses, CoV, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus

ORLANDO, Fla., Sept. 15, 2020 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), announced that it has agreed terms with Irish based Oran Textiles Ltd. for the US and Korean distribution rights for Oran Textiles V-block coated facemasks.

Key Points: 
  • ORLANDO, Fla., Sept. 15, 2020 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), announced that it has agreed terms with Irish based Oran Textiles Ltd. for the US and Korean distribution rights for Oran Textiles V-block coated facemasks.
  • HeiQ's V-Block technology shown strong antimicrobial efficacy demonstrated by ISO 20743 and ISO 18184 tests.
  • HeiQ's V-Block technology is a patent pending combination of advanced silver and vesicle booster technology.
  • HEIQ V-BLOCK NPJ03 received positive results against SARS-CoV-2 in laboratory testing at the Doherty Institute for infection and immunity in Melbourne, Australia.

Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

Retrieved on: 
Wednesday, July 22, 2020
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Virology, Medical specialties, Laboratory techniques, Zoonoses, Natural sciences, Chemistry, Plaque reduction neutralization test, Peplomer, Coronavirus disease, NIHS, CoV, Assay

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) announces that the National Institutes of Health (the NIH) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.
  • The NIHs preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer (PRNT) assay.
  • In March 2020 Noachis Terra Inc., a wholly owned subsidiary of Oragenics, acquired a non-exclusive license from the NIH for this stabilized prefusion CoV-2 spike protein.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Aquionics, Berson & Hanovia Launch New UVC Device for Inactivation of SARS-CoV-2

Retrieved on: 
Tuesday, July 14, 2020
Other Manufacturing, Environment, Commercial Building & Real Estate, Construction & Property, Infectious diseases, Manufacturing, Building Systems, Health, General Health, Electrodynamics, Ultraviolet radiation, Building biology, Zoonoses, Electromagnetic radiation, Electromagnetic spectrum, Ultraviolet, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, CoV, Berson, Virus

Halmas UV Group of companies (Aquionics, Berson & Hanovia) today announced the launch of the AirLine UVv, a UVC device for HVAC systems ( www.weuvcare.com/airline-uv/ ) that will help put an end to harmful pathogens, such as SARS-CoV-2, the virus which causes COVID-19.

Key Points: 
  • Halmas UV Group of companies (Aquionics, Berson & Hanovia) today announced the launch of the AirLine UVv, a UVC device for HVAC systems ( www.weuvcare.com/airline-uv/ ) that will help put an end to harmful pathogens, such as SARS-CoV-2, the virus which causes COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20200714005955/en/
    Aquionics, Berson & Hanovia today announced the launch of the AirLine UVv, a UVC device for commercial HVAC systems that will help put an end to harmful pathogens, such as SARS-CoV-2, the virus which causes COVID-19.
  • The AirLine UVv high output lamps provide just that, sufficient UVC to eliminate up to 99.99% of harmful pathogens in high velocity airflow.
  • Aquionics, located in Charlotte, NC-USA, Berson located in Nuenen, NL and Hanovia located in Slough (UK) & Shanghai, protect the worlds critical resources without using chemicals.

Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2

Retrieved on: 
Monday, July 13, 2020
Viruses, Coronaviridae, Zoonoses, Emergency Use Authorization, Food and Drug Administration, Animal virology, CoV, Severe acute respiratory syndrome, Coronavirus, Qiagen

NEW YORK, NY, July 13, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it has formally received Emergency Use Authorization (EUA) for its proprietary product for the detection of Coronavirus SARS-CoV-2.

Key Points: 
  • NEW YORK, NY, July 13, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it has formally received Emergency Use Authorization (EUA) for its proprietary product for the detection of Coronavirus SARS-CoV-2.
  • These platforms include Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.
  • The AMPIPROBE SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and the AMPIPROBE SARS-CoV-2 Assay Kit for detection and analysis.
  • Pursuant to receiving the Emergency Use Authorization, Enzos diagnostics division is offering the AMPIPROBE SARS-Cov-2 Test System for use with three platforms.

NovaBay Pharmaceuticals Announces Laboratory Results Confirm Avenova Kills SARS-CoV-2 (COVID-19 Virus)

Retrieved on: 
Monday, July 13, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Viruses, Chemical substances, Animal virology, Microbiology, Zoonoses, Coronaviridae, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, CoV, Disinfectant, Hypochlorous acid

(NYSE American: NBY) announces testing results from an independent third-party laboratory confirming that Avenova, NovaBays proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

Key Points: 
  • (NYSE American: NBY) announces testing results from an independent third-party laboratory confirming that Avenova, NovaBays proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.
  • Test results will be submitted to the Environmental Protection Agency (EPA) for the EPAs approved list of disinfectants for use against SARS-CoV-2.
  • Now we have results from a highly reputable independent laboratory confirming Avenova kills the coronavirus that causes COVID-19, said Justin Hall, NovaBay CEO.
  • The study was designed to determine Avenovas effectiveness against the SARS-CoV-2 on a hard surface.

New England Biolabs' SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit Enables Visual Detection of Novel Coronavirus In 30 Minutes

Retrieved on: 
Friday, July 10, 2020
Viruses, Nidovirales, Zoonoses, Coronaviridae, Laboratory techniques, Health in Saudi Arabia, In Saudi Arabia, Middle East respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, CoV

IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.

Key Points: 
  • IPSWICH, Mass., July 10, 2020 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, a Research Use Only (RUO) product that can be used for the detection of novel coronavirus, SARS-CoV-2 RNA.
  • The kit serves as a simple alternative to RT-qPCR and enables visual detection of amplification of SARS-CoV-2 nucleic acid in just 30 minutes.
  • "With the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, all you need is a simple heat source and 30 minutes to visually detect amplification of SARS CoV-2 RNA.
  • NEB,NEW ENGLAND BIOLABS, and WarmStart are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-sars-cov-2-r...

Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

Retrieved on: 
Friday, July 10, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Health, Medicine, Zoonoses, Clinical research, Severe acute respiratory syndrome-related coronavirus, CoV, Mucositis, Severe acute respiratory syndrome, Antibiotic, Clinical trial, Vaccine

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.
  • The Company expects to continue to comply with any applicable regulatory requirements with respect to discontinuing the clinical trial.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. relating to the development of novel antibiotics.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein, except as required by law.